TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.

• Source: tcr2
• 505
• March 23, 2018